570 related articles for article (PubMed ID: 28161703)
41. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
[TBL] [Abstract][Full Text] [Related]
42. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
43. Computed Tomography and Magnetic Resonance Imaging in the Diagnosis of Primary Neuroendocrine Tumors of the Liver.
Han Y; Li L; Sun H
World Neurosurg; 2020 Jun; 138():723-731. PubMed ID: 32006738
[TBL] [Abstract][Full Text] [Related]
44. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
Raj N; Valentino E; Capanu M; Tang LH; Basturk O; Untch BR; Allen PJ; Klimstra DS; Reidy-Lagunes D
Pancreas; 2017 Mar; 46(3):296-301. PubMed ID: 27759713
[TBL] [Abstract][Full Text] [Related]
45. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
De Divitiis C; von Arx C; Grimaldi AM; Cicala D; Tatangelo F; Arcella A; Romano GM; Simeone E; Iaffaioli RV; Ascierto PA; Tafuto S;
J Transl Med; 2016 May; 14(1):113. PubMed ID: 27142424
[TBL] [Abstract][Full Text] [Related]
46. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Sorbye H; Kong G; Grozinsky-Glasberg S
Endocr Relat Cancer; 2020 Mar; 27(3):R67-R77. PubMed ID: 31846429
[TBL] [Abstract][Full Text] [Related]
47. The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution.
Kim ST; Ha SY; Lee J; Hong SN; Chang DK; Kim YH; Park YA; Huh JW; Cho YB; Yun SH; Lee WY; Kim HC; Park YS
Medicine (Baltimore); 2016 May; 95(19):e3534. PubMed ID: 27175651
[TBL] [Abstract][Full Text] [Related]
48. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.
Hadoux J; Malka D; Planchard D; Scoazec JY; Caramella C; Guigay J; Boige V; Leboulleux S; Burtin P; Berdelou A; Loriot Y; Duvillard P; Chougnet CN; Déandréis D; Schlumberger M; Borget I; Ducreux M; Baudin E
Endocr Relat Cancer; 2015 Jun; 22(3):289-98. PubMed ID: 25770151
[TBL] [Abstract][Full Text] [Related]
49. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3).
Sorbye H; Baudin E; Borbath I; Caplin M; Chen J; Cwikla JB; Frilling A; Grossman A; Kaltsas G; Scarpa A; Welin S; Garcia-Carbonero R;
Neuroendocrinology; 2019; 108(1):54-62. PubMed ID: 30153658
[TBL] [Abstract][Full Text] [Related]
50. Prognoses in patients with primary gastrointestinal neuroendocrine neoplasms based on the proposed new classification scheme.
Yin XN; Shen CY; Yin YQ; Chen HJ; Chen HN; Yin Y; Han LY; Chen JJ; Tang SM; Chen ZX; Zhang B
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e37-e44. PubMed ID: 28856815
[TBL] [Abstract][Full Text] [Related]
51. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
[TBL] [Abstract][Full Text] [Related]
52. EpiCO (epirubicin, cyclophosphamide and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms.
Munker S; Vogelhuber M; Bornschein J; Stroszczynski C; Evert M; Schlitt H; Herr W; Teufel A
Z Gastroenterol; 2020 Feb; 58(2):133-136. PubMed ID: 31896137
[TBL] [Abstract][Full Text] [Related]
53. Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.
Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Iwasaki T; Takenaga N; Kasahara Y; Ouchi K; Shirota H; Takahashi M; Ishioka C
Oncology; 2024; 102(5):359-367. PubMed ID: 37903486
[TBL] [Abstract][Full Text] [Related]
54. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
55. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
Araki T; Takashima A; Hamaguchi T; Honma Y; Iwasa S; Okita N; Kato K; Yamada Y; Hashimoto H; Taniguchi H; Kushima R; Nakao K; Boku N; Shimada Y
Anticancer Drugs; 2016 Sep; 27(8):794-9. PubMed ID: 27341105
[TBL] [Abstract][Full Text] [Related]
56. Classification and Prognostic Stratification of Bronchopulmonary Neuroendocrine Neoplasms.
Oka N; Kasajima A; Konukiewitz B; Sakurada A; Okada Y; Kameya T; Weichert W; Ishikawa Y; Suzuki H; Sasano H; Klöppel G
Neuroendocrinology; 2020; 110(5):393-403. PubMed ID: 31422400
[TBL] [Abstract][Full Text] [Related]
57. Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):11-3. PubMed ID: 27168106
[No Abstract] [Full Text] [Related]
58. Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.
Hinterleitner M; Pfeiffer R; Trautwein NF; Sipos B; Singer S; Nadalin S; Königsrainer A; Lauer UM; la Fougère C; Zender L; Hinterleitner C
Front Endocrinol (Lausanne); 2023; 14():1285529. PubMed ID: 38260136
[TBL] [Abstract][Full Text] [Related]
59. The treatment of undifferentiated neuroendocrine tumors.
Mitry E; Rougier P
Crit Rev Oncol Hematol; 2001 Jan; 37(1):47-51. PubMed ID: 11164718
[TBL] [Abstract][Full Text] [Related]
60. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
